Stockreport

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the e...

Merus N.V. - Common Shares  (MRUS) 
Last merus n.v. - common shares earnings: 8/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/mrus
PDF Merus and Partner Therapeutics announced a license agreement for U.S. commercialization UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) [Read more]